Modus Therapeutics

Focus: Modus Therapeutics is a Swedish biotech company founded in 2020 focused on heparin derivatives for infectious diseases and cardiovascular indications. The company is publicly listed but operates at an early clinical stage with a lean pipeline.

Infectious Diseases Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Modus Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Modus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Minimally-Invasive Segmental Artery Coil-Embolization

Aortic Aneurysm, Thoracoabdominal

N/A

Clinical Trials (1)

NCT03434314Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging

N/A

Help build intelligence for Modus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape development of novel heparin-derivative platform across malaria, sickle-cell disease, and smoking cessation indications
Public company status provides liquidity and potential upside while maintaining biotech agility and focus
Swedish base offers access to European regulatory pathways and healthcare markets

Watch Out For

Minimal clinical validation: only 4 active trials across Phase 1-2 with no Phase 3 programs reduces near-term approval probability
Zero current job openings and lack of hiring signals suggest early-stage constraints on team expansion and career mobility
Limited public financial data, no revenue, and sparse publication record create visibility gaps on company stability and scientific credibility

Generated by Claude from Modus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Sevuparin

Safety and Tolerability

Phase 1

Clinical Trials (1)

NCT03853421Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin

Phase 1

Sevuparin sodium + atovaquone/proquanil

Malaria, Falciparum

Phase 1/2

Clinical Trials (1)

NCT01442168Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

Phase 1/2